✨
Yapay Zeka Hızlı Bakış & Çıkarımlar
AI Insight⚡ TL;DR(1 Cümlede Hızlı Çıkarım)
This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Nivolumab is a monoclonal antibody against programmed cell death protein-1 which is assessed in the group of immune checkpoint inhibitors.
📊
Temel Bulgular & Veri:In this article, we report a 38-year-old male patient diagnosed with seronegative arthritis after nivolumab therapy.
💡
Sonuç & Katkı:This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
Nivolumab is a monoclonal antibody against programmed cell death protein-1 which is assessed in the group of immune checkpoint inhibitors. It may lead to immune-related adverse events. In this article, we report a 38-year-old male patient diagnosed with seronegative arthritis after nivolumab therapy. This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.
🔖
Bu Makaleye Atıf Yap
ÇOLAK, S., OMMA, A. (2019). Nivolumab Induced Seronegative Arthritis in a Patient With Refractory Hodgkin’s Lymphoma. art, Cilt: 34 - Sayı: 1, 112–114. https://ajindex.com/articles/149682